Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide…

Overview of attention for article published in BMC Cancer, May 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 26 Dimensions

Readers on

mendeley: 66 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 2 X users, with an upper bound of 1,735 followers.

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. https://t

27 Nov 2019

Reply Repost Favourite

RT @palliativewise: Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on…

26 Nov 2019

Reply Repost Favourite

26 Nov 2019

Reply Repost Favourite

30 May 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.